αv Integrins as Receptors for Tumor Targeting by Circulating Ligands

Nature Biotechnology

Volumn 15, Issue 6, 1997, Pages 542-546

  Pasqualini, Renata ^a   Koivunen, Erkki ^b   Ruoslahti, Erkki ^a  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiogenesis; Integrins; Phage display; RGD; Tumor targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; INTEGRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOPHAGE; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; LIGAND BINDING; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; BACTERIOPHAGES; BREAST NEOPLASMS; DRUG CARRIERS; FEMALE; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; RECEPTORS, VITRONECTIN; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA;

EID: 0030940283     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0697-542     Document Type: Article

References (32)

1. Pauli, B.U., Augustin-Voss, H.G., El-Sabban, M.E., Johnson, R.C., and Hammer, D.A. 1990. Organ-preference of metastasis. The role of endothelial cell adhesion molecules. Cancer Metastasis Rev. 9:175-189.
2. Zetter, B.R. 1990. The cellular basis of site-specific tumor metastasis. N. Engl. J. Med. 322:605-612.
3. Springer, T.A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301-314.
4. Butcher, E.C. and Picker, L.J. 1996. Lymphocyte homing and homeostasis. Science 272:60-66.
5. Goetz, D.J., El-Sabban, M.E., Hammer, D.A., and Pauli, B.U. 1996. Lu-ECAM-1-mediated adhesion of melanoma cells to endothelium under conditions of flow. Int. J. Cancer 65:192-199.
6. Pasqualini, R. and Ruoslahti, E. 1996. Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366.
7. Baillie, C.T., Winslet, M.C., and Bradley, N.J. 1995. Tumour vasculature—a potential therapeutic target. Br. J. Cancer 72:257-267.
8. Burrows, F.J. and Thorpe, P.E. 1994. Vascular targeting—a new approach to the therapy of solid tumors. Pharmacol. Ther. 64:155-174.
9. Buckle, R. 1994. Vascular targeting and the inhibition of angiogenesis. Ann. Oncol. 4(suppl.):45-50.
10. Mustonen, T. and Alitalo, K. 1995. Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. 129:895-898.
11. Lappi, D.A. 1995. Tumor targeting through fibroblast growth factor receptors. Semin. Cancer Biol. 6:279-288.
12. Martiny-Baron, G. and Marme, D. 1995. VEGF-mediated tumor angiogenesis: a new target for cancer therapy. Curr. Opin. Biotechnol. 6:675-680.
13. Rettig, W.J., Garin-Chesa, P., Healey, J.H., Su, S.L., Jaffe, E.A., and Old, L.J. 1992. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc. Natl. Acad. Sci. USA 89:10832-10836.
14. Brooks, P.C., Clark R.A., and Cheresh, D.A. 1994. Requirement of vascular integrin αvß3 for angiogenesis. Science 264:569-571.
15. Friedlander, M., Brooks, P.C., Sharffer, R.W., Kincaid, C.M., Varner, J.A., and Cheresh, D.A. 1995. Definition of two angiogenic pathways by distinct αv integrins. Science 270:1500-1502.
16. Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., et al. 1994. Integrin αvß3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.
17. Brooks, P.C., Stromblad S., Klemle R., Visscher D., Sarkar F.H., and Cheresh, D.A. 1995. Anti-integrin αvß3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1815-1822.
18. Hammes, H.-P., Brownlee, M., Joonczyk, A., Sutter, A., and Preissner, K.T. 1996. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature. Med. 5:529-533.
19. Conforti, G., Dominguew-Jimenez, O., Zanetti, A., Gimbrone, M.A., Cremona, O., Marchisio, P.C., et al. 1992. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood 80:437-446.
20. Smith, G.P. and Scott, J.K. 1993. Libraries of peptides and proteins displayed in filamentous phage. Methods Enzymol. 21:228-257.
21. Ruoslahti, E. 1996. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:697-715.
22. Koivunen, E., Wang, B., and Ruoslahti, E. 1995. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio/Technology 13:265-270.
23. Geter, M.R., Trigg, M.E., and Merril, C.R. 1973. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246:221-223.
24. Shockley, T.R., Lin, K., Nagy, J.A., Tompkins, R.G., Dvorak, H.F., and Yarmush, M.L. 1991. Penetration of tumor tissue by antibodies and other immunoproteins. Ann. N.Y. Acad. Sci. 618:367-382.
25. Dvorak, H.F., Nagy, J.A., and Dvorak, A.M. 1991. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3:77-85.
26. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:27-31.
27. Hanahan, D. and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
28. Rak, J.W., St. Croix, B.D., and Kerbel, R.S. 1995. Consequences of angiogenesis for tumor progression, metastasis and cancer. Anticancer Drugs 6:3-18.
29. Price, J.E., Polyzos, A., Zhang, R.D., and Daniels, L.M. 1990. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res. 50:717-721.
30. Nicolson, G.L., Inoue, T., Van Pelt, C.S., and Cavanaugh, P.G. 1990. Differential expression of a Mr. approximately 90,000 cell surface transferrin receptor-related glycoprotein on murine B16 metastatic melanoma sublines selected for enhanced brain or ovary colonization. Cancer Res. 50:515-520.
31. Welch, D.R., Bisi, J.E., Miller, B.E., Conaway, D., Seftor, E.A., Yohem, K.H., et al. 1991. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int. J. Cancer 47:227-237.
32. Montesano, R., Pepper, M.S., Möhle-Steinlein, U., Risau, W., Wagner, E.F., and Orci, L. 1990. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62:435-445.